|Datasheet||Specific References||Reviews||Related Products||Protocols|
|ORF Clone of lysozyme-like 2 DNA.|
|Identical with the Gene Bank Ref. ID sequence.|
|Whatman FTA elute card (Cat: WB120410) contains 5-10 μg of plasmid.|
|The Whatman FTA elute card can be stored at room temperature for three months under dry condition.|
The pGEM-T is 3kb in length, and contains the amplicin resistance gene, conferring selection of the plasmid in E. coli, and the ori site which is the bacterial origin of replication. The plasmid has multiple cloning sites as shown below. The coding sequence was inserted by TA cloning. Many E. coli strains are suitable for the propagation of this vector including JM109, DH5α and TOP10.
The coding sequence can be easily obtained by digesting the vector with proper restriction enzyme(s). The coding sequence can also be amplified by PCR with M13 primers, or primer pair SP6 and T7.
|Human LYZL2 Gene cDNA Clone (full-length ORF Clone), expression ready, FLAG-tagged||HG13726-G-F|
|Human LYZL2 Gene cDNA Clone (full-length ORF Clone), expression ready, His-tagged||HG13726-G-H|
|Human LYZL2 Gene cDNA Clone (full-length ORF Clone), expression ready, Myc-tagged||HG13726-G-M|
|Human LYZL2 Gene cDNA Clone (full-length ORF Clone), expression ready, untagged||HG13726-G-N|
|Human LYZL2 Gene cDNA Clone (full-length ORF Clone), expression ready, HA-tagged||HG13726-G-Y|
|Product name||Product name|
Lysozyme 2 gene is a member of a family of lysozyme-like genes. Lysozymes, especially C-type lysozymes, are well-recognized bacteriolytic factors widely distributed in the animal kingdom and play a mainly protective role in host defense. Lysozymes damage bacterial cell walls by catalyzing hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in a peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrins.
Lysozyme is part of the innate immune system. Reduced lysozyme levels have been associated with bronchopulmonary dysplasia in newborns. In certain cancers (especially myelomonocytic leukemia) excessive production of lysozyme by cancer cells can lead to toxic levels of lysozyme in the blood. High lysozyme blood levels can lead to kidney failure and low blood potassium, conditions that may improve or resolve with treatment of the primary malignancy.